-inc-logo-1200x675.jpg?v=20240515130629){kind=logo}
Definium Therapeutics (NASDAQ:DFTX – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a report released on Monday, Benzinga reports. They presently have a $70.00 price objective on the stock. HC Wainwright’s target price would indicate a potential upside of 72.41% from the company’s previous close.
Other research analysts also recently issued research reports about the company. Wells Fargo & Company boosted their price target on Definium Therapeutics from $68.00 to $72.00 and gave the company an “overweight” rating in a report on Thursday, August 13th. JonesTrading increased their price objective on Definium Therapeutics from $74.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. Leerink Partners set a $52.00 target price on Definium Therapeutics and gave the company an “outperform” rating in a research note on Monday, June 22nd. Maxim Group set a $55.00 target price on Definium Therapeutics and gave the company a “buy” rating in a research note on Friday, August 14th. Finally, Oppenheimer restated an “outperform” rating and set a $70.00 target price on shares of Definium Therapeutics in a report on Wednesday, August 12th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Definium Therapeutics currently has a consensus rating of “Buy” and an average target price of $63.00.
Get Our Latest Stock Report on DFTX
Definium Therapeutics Trading Up 4.4%
Definium Therapeutics (NASDAQ:DFTX – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.89). Analysts forecast that Definium Therapeutics will post -3.02 EPS for the current fiscal year.
Insider Buying and Selling at Definium Therapeutics
In other news, insider Matthew T. Wiley sold 2,867 shares of Definium Therapeutics stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $129,101.01. Following the completion of the transaction, the insider directly owned 174,633 shares in the company, valued at approximately $7,863,723.99. This trade represents a 1.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Robert Barrow sold 19,023 shares of the business’s stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $37.94, for a total value of $721,732.62. Following the completion of the sale, the chief executive officer directly owned 1,494,640 shares in the company, valued at approximately $56,706,641.60. This represents a 1.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 67,119 shares of company stock worth $2,887,496. Insiders own 2.40% of the company’s stock.
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. grew its stake in shares of Definium Therapeutics by 110.4% in the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after acquiring an additional 2,003 shares during the last quarter. Nykredit A S purchased a new position in shares of Definium Therapeutics in the 2nd quarter worth about $45,000. BNP Paribas Financial Markets raised its position in shares of Definium Therapeutics by 56.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock worth $55,000 after purchasing an additional 3,020 shares during the last quarter. Allworth Financial LP bought a new position in Definium Therapeutics in the 2nd quarter worth about $110,000. Finally, Caxton Associates LLP bought a new position in Definium Therapeutics in the 3rd quarter worth about $126,000. Hedge funds and other institutional investors own 27.91% of the company’s stock.
More Definium Therapeutics News
Here are the key news stories impacting Definium Therapeutics this week:
- Positive Sentiment: Definium reported that its second Phase 3 study of DT120 ODT met its primary endpoint, showing a statistically significant improvement in anxiety symptoms among patients with GAD. The successful result follows positive findings from an earlier late-stage study, providing additional support for the drug’s potential efficacy. Definium’s LSD-based drug lowers anxiety in second successful late-stage study
- Positive Sentiment: The company’s Panorama Phase 3 trial achieved its goal, with topline data indicating meaningful anxiety improvement. Investors are likely viewing the readout as an important step toward a potential regulatory submission for DT120 ODT. Definium Therapeutics Announces Positive Topline Results
- Positive Sentiment: Needham reaffirmed its Buy rating and set a $66 price target, while Royal Bank of Canada previously assigned an Outperform rating. The bullish analyst views add support to the positive market reaction. Definium Therapeutics Earns Outperform Rating
- Neutral Sentiment: Trading in DFTX was temporarily halted for pending news before the clinical announcement, reflecting heightened volatility around the Phase 3 disclosure. The company also scheduled a webcast to discuss the results. Definium to Discuss Topline Results
- Neutral Sentiment: Definium granted options covering 56,650 shares to three new employees. The grants may create limited future dilution but are primarily intended as hiring incentives. Definium Announces New Employee Inducement Grants
Definium Therapeutics Company Profile
Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.
Featured Articles
- Five stocks we like better than Definium Therapeutics
- Fabrinet, Dycom and Qualcomm: 3 AI Fallen Angels Wall Street Just Marked Down
- 3 European Banks That Could Win Big From ECB Rate Hikes
- SM Energy’s Civitas Merger Is Paying Off, But the Stock’s Run Raises the Bar
- Intel’s Price Hikes Could Put $120 Back in Play
Receive News & Ratings for Definium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Definium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
